Glass House Brands (GLAS) Total Liabilities (2020 - 2026)
Glass House Brands (GLAS) posted quarterly Total Liabilities of $147.9 million for Q1 2026, up 7.94% year-over-year from $137.0 million in Q1 2025, and up 2.74% quarter-over-quarter from $144.0 million in Q4 2025.
Glass House Brands (GLAS) Total Liabilities (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has reported Total Liabilities for 7 consecutive years, with $147.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 7.94% year-over-year to $147.9 million; the TTM figure through Mar 2026 stood at $147.9 million (up 7.94% YoY), while the FY2025 annual figure was $144.0 million, down 1.7% from the prior year.
- Total Liabilities climbed to $147.9 million in Q1 2026 per GLAS's latest filing, from $144.0 million in the prior quarter.
- Across five years, Total Liabilities topped out at $170.6 million in Q3 2023 and bottomed at $110.2 million in Q1 2022.
- Historically, Total Liabilities has averaged $146.4 million across 5 years, with a median of $144.0 million in 2025.
- On a YoY basis, Total Liabilities climbed as much as 303.18% in 2022 and fell as far as 77.09% in 2022.
- Glass House Brands' Total Liabilities stood at $129.5 million in 2022, then rose by 22.43% to $158.5 million in 2023, then declined by 7.63% to $146.4 million in 2024, then slipped by 1.7% to $144.0 million in 2025, then grew by 2.74% to $147.9 million in 2026.
- Business Quant data shows GLAS's Total Liabilities at $147.9 million in Q1 2026, $144.0 million in Q4 2025, and $138.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | -21.66 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 32.10 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 11.93 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 50.85 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 819.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 20.78 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 1.67 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 6.97 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 2.12 Bn |
| 10 | Glass House Brands | 825.81 Mn | 807.26 Mn | 15.77 Mn | 148.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 147.91 Mn |
| Dec 31, 2025 | 143.96 Mn |
| Sep 30, 2025 | 138.06 Mn |
| Jun 30, 2025 | 142.25 Mn |
| Mar 31, 2025 | 137.03 Mn |
| Dec 31, 2024 | 146.45 Mn |
| Sep 30, 2024 | 163.00 Mn |
| Jun 30, 2024 | 159.16 Mn |
| Mar 31, 2024 | 166.84 Mn |
| Dec 31, 2023 | 158.54 Mn |
| Sep 30, 2023 | 170.56 Mn |
| Jun 30, 2023 | 165.13 Mn |
| Mar 31, 2023 | 137.83 Mn |
| Dec 31, 2022 | 129.49 Mn |
| Sep 30, 2022 | 129.86 Mn |
| Jun 30, 2022 | 142.46 Mn |
| Mar 31, 2022 | 110.19 Mn |
| Dec 31, 2021 | 105.65 Mn |
| Sep 30, 2021 | 65.71 Mn |
| Jun 30, 2021 | 35.33 Mn |